Ngai, W., Li, S. D., MacNeil, S., Ren, M., Ji, S., Koloskova, J. (2026). First-line lenvatinib versus dabrafenib plus trametinib (D+T) in
                    <i>BRAF</i>
                    -mutated differentiated thyroid cancer (DTC): Insights from real-world data.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.6052